摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯-4-硝基-N-(5-硝基-2-噻唑基)苯甲酰胺 | 380623-76-7

中文名称
3-氯-4-硝基-N-(5-硝基-2-噻唑基)苯甲酰胺
中文别名
3-氯-4-硝基-N-(5-硝基噻唑-2-基)苯甲酰胺
英文名称
3-Chloro-4-nitro-N-(5-nitro-2-thiazolyl)-benzamide
英文别名
3-chloro-4-nitro-N-(5-nitro-1,3-thiazol-2-yl)benzamide
3-氯-4-硝基-N-(5-硝基-2-噻唑基)苯甲酰胺化学式
CAS
380623-76-7
化学式
C10H5ClN4O5S
mdl
——
分子量
328.69
InChiKey
XCHLNGBTHLJLFG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    162
  • 氢给体数:
    1
  • 氢受体数:
    7

文献信息

  • Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
    申请人:The Regents of the University of California
    公开号:US10029017B2
    公开(公告)日:2018-07-24
    Disclosed herein, the invention pertains to methods and compositions that find use in treatment, diagnosis, prognosis and characterization of disease and disease samples based on the ability of a disease sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is a pre-targeting moiety; M is a macromolecular carrier, C is a detectable moiety; and T is a compound for delivery to a target, including for example a therapeutic compound.
    在此公开的本发明涉及根据疾病样本裂解本发明的 MTS 分子的能力用于疾病和疾病样本的治疗、诊断、预后和表征的方法和组合物。本发明的 MTS 分子具有如本文所公开的式,其中 A 是多肽,其序列包括 5 至 9 个连续的酸性氨基酸,其中氨基酸选自天冬氨酸和谷酸;B 是多肽,其序列包括 5 至 20 个连续的碱性氨基酸;X 和 Y 是连接体;P 是预靶向分子;M 是大分子载体;C 是可检测分子;T 是用于递送至靶点的化合物,例如包括治疗化合物。
  • Personalized protease assay to measure protease activity in neoplasms
    申请人:The Regents of the University of California
    公开号:US10385380B2
    公开(公告)日:2019-08-20
    Disclosed herein, the invention pertains to methods and compositions that find use in diagnostic, prognostic and characterization of neoplasia samples based on the ability of a neoplasia sample to cleave a MTS molecule of the present invention. In some embodiments, a MTS molecule disclosed herein has the formula (A-X-B-C), wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and C is a detectable moiety.
    本发明涉及根据肿瘤样本裂解本发明 MTS 分子的能力,用于诊断、预后和表征肿瘤样本的方法和组合物。在一些实施方案中,本发明公开的 MTS 分子具有式(A-X-B-C),其中 A 是多肽,其序列包括 5 至 9 个连续的酸性氨基酸,其中氨基酸选自天冬氨酸和谷酸;B 是多肽,其序列包括 5 至 20 个连续的碱性氨基酸;X 是连接体;C 是可检测分子。
  • Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
    申请人:The Regents of the University of California
    公开号:US10596259B2
    公开(公告)日:2020-03-24
    Disclosed herein, the invention pertains to methods and compositions that find use in radiosensitization of tumors and tumor samples based on the ability of a tumor sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is an optional pre-targeting moiety; M is an optional macromolecular carrier; and T is a radiosensitization agent for delivery to a target, including for example a therapeutic compound.
    本发明涉及根据肿瘤样品裂解本发明MTS分子的能力对肿瘤和肿瘤样品进行放射增敏的方法和组合物。本发明的MTS分子具有如本文所公开的式,其中A是具有包含5至9个连续酸性氨基酸序列的多肽,其中氨基酸选自天冬氨酸和谷酸;B是具有包含5至20个连续碱性氨基酸序列的多肽;X和Y是连接体;P是任选的前靶向分子;M是任选的大分子载体;T是用于递送至靶点(例如包括治疗化合物)的放射增敏剂。
  • Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic delivery
    申请人:The Regents of the University of California
    公开号:US11021517B2
    公开(公告)日:2021-06-01
    The present invention provides methods for guiding preservation of human neurons or human nerves during surgery by administering a fluorescently-labeled peptide that specifically binds to the human neurons or human nerves. The invention further provides human neuron or nerve targeting molecules comprising fluorescently-labeled peptides that specifically bind to human neurons or human nerves and compositions thereof.
    本发明提供了在手术过程中通过施用能与人神经元或人神经特异性结合的荧光标记肽来指导保存人神经元或人神经的方法。本发明进一步提供了人类神经元或神经靶向分子,包括特异性结合人类神经元或人类神经的荧光标记肽及其组合物。
  • Peptides whose uptake in cells is controllable
    申请人:The Regents of the University of California
    公开号:US11246940B2
    公开(公告)日:2022-02-15
    Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier.
    在某些实施方案中,本文公开了一种体内循环增加的选择性转运分子。在某些实施方案中,本文公开的选择性转运分子具有式(A-X-B-C)-M,其中 C 是货物分子;A 是多肽,其序列包括 5 至 9 个连续的酸性氨基酸,其中氨基酸选自天冬氨酸和谷酸;B 是多肽,其序列包括 5 至 20 个连续的碱性氨基酸;X 是连接体;M 是大分子载体。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫